• About Us
  • Our Approach
    • Discovery Platform
  • Pipeline
    • HMBD-001
    • HMBD-002
    • HMBD-501
  • News & Publications
  • Careers

What are you looking for?

Hummingbird Bioscience
Hummingbird Bioscience
Hummingbird Bioscience
  • About Us
  • Our Approach
    • Discovery Platform
  • Pipeline
    • HMBD-001
    • HMBD-002
    • HMBD-501
  • News & Publications
  • Careers

    communications@hummingbirdbio.com

  • All
  • Announcements
  • News
  • Publications & Posters
    • Publications & Posters
    • Publications & Posters – 2023

    Combining anti-HER3 antibody, HMBD-001, with EGFR inhibition and chemotherapy may improve treatment outcomes in squamous NSCLC

    Continue Reading
    • Announcements
    • Announcements 2023

    Hummingbird Bioscience to Present Poster on HMBD-001 Combination Strategy for Squamous Non-Small Cell Lung Cancer at World Conference on Lung Cancer 2023

    Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat…

    Continue Reading
    • Publications & Posters
    • Publications & Posters – 2023

    HMBD-002 A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors

    Continue Reading
    • Announcements
    • Announcements 2022

    Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023

    Continue Reading
    • Publications & Posters
    • Publications & Posters – 2023

    HMBD-011 Targeting pathogenic auto-reactive VH4-34 B cells with a rationally developed and highly specific anti-VH4-34 antibody offers a new therapeutic approach for VH4-34 autoimmune disorders

    Continue Reading
    • Announcements
    • Announcements 2023

    Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma

    Continue Reading
    • Announcements
    • Announcements 2023

    Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases

    Continue Reading
    • Publications & Posters
    • Publications & Posters – 2023

    Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker selected pre-clinical models of squamous cell carcinomas

    Continue Reading
    • Publications & Posters
    • Publications & Posters – 2023

    HMBD-501 – a novel Fc engineered, exatecan-based next-generation HER3-targeting Antibody-Drug Conjugate (ADC) shows robust tolerability and efficacy in pre-clinical solid tumor models

    Continue Reading
    • Announcements
    • Announcements 2023

    Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023

    Continue Reading
  • 1
  • 2
  • →

Hummingbird Bioscience

TMC Innovation
2450 Holcombe Blvd, Suite X
Houston, TX 77021

The Galen
61 Science Park Road, #06-15/24,
Singapore 117525

For general enquiries, please contact contact@hummingbirdbio.com

For career enquiries, please contact careers@hummingbirdbio.com

For business development opportunities, please contact bd@hummingbirdbio.com


Hummingbird Bioscience Twitter Hummingbird Bioscience Twitter Hummingbird Bioscience LinkedinHummingbird Bioscience Linkedin Hummingbird Bioscience YouTube Hummingbird Bioscience YouTube
Subscribe to our updates
Registered Company No: 201505192N
PRIVACY POLICY | © 2023 Hummingbird Bioscience

Subscribe to our updates

    *indicates required

    You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website. For questions about this mailing list, please email communications@hummingbirdbio.com

    We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.